Abstract:We performed a meta‐analysis with 24 observational studies concerning the effect of Chinese COVID‐19 patients with azvudine. We discovered that azvudine offers a good protective effect and safety profile, significantly reducing mortality of COVID‐19 patients. However, the low certainty of the evidence leads us to adopt a cautious stance regarding this conclusion. Background Azvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are still unclear. This study aimed to evaluate the protective effect of FNC on COVID‐19 outcomes and its safety. Methods We followed the PRISMA 2020 guidelines and searched the PubMed, Embase, Web of Science, Scopus, and China National Knowledge Infrastructure (CNKI) databases to evaluate studies on the effectiveness of FNC in treating COVID‐19 in China, focusing on mortality and overall outcomes. Additionally, its impact on the length of hospital stay (LOHS), time to first nucleic acid negative conversion (T‐FNANC), and adverse events was evaluated. The inclusion criterion was that the studies were published from July 2021 to April 10, 2024. This study uses the ROBINS‐I tool to assess bias risk and employs the GRADE approach to evaluate the certainty of the evidence. Results The meta‐analysis included 24 retrospective studies involving a total of 11 830 patients. Low‐certainty evidence revealed no significant difference in mortality (OR = 0.91, 95% CI: 0.76–1.08) or LOHS (WMD = −0.24, 95% CI: −0.83 to 0.35) between FNC and Paxlovid in COVID‐19 patients. Low‐certainty evidence shows that the T‐FNANC was longer (WMD = 1.95, 95% CI: 0.36–3.53). Compared with the Paxlovid group, low‐certainty evidence shows the FNC group exhibited a worse composite outcome (OR = 0.77, 95% CI: 0.63–0.95) and fewer adverse events (OR = 0.63, 95% CI: 0.46–0.85). Compared with supportive treatment, low certainty shows FNC significantly reduced the mortality rate in COVID‐19 patients (OR = 0.61, 95% CI: 0.51–0.74) and decreased the composite outcome (OR = 0.67, 95% CI: 0.50–0.91), and very low certainty evidence shows significantly decreased the T‐FNANC (WMD = −4.62, 95% CI: −8.08 to −1.15). However, in very low certainty, there was no significant difference in LOHS (WMD = −0.70, 95% CI: −3.32 to 1.91) or adverse events (OR = 1.97, 95% CI: 0.48–8.17). Conclusions FNC appears to be a safe and potentially effective treatment for COVID‐19 in China, but further research with larger, high‐quality studies is necessary to confirm these findings. Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are applicable worldwide. Trial Registration PROSPERO number: CRD42024520565

Cost-effectiveness of Azvudine for High-risk Outpatients With Mild-to-moderate Coronavirus Disease 2019 in China

Real-world Effectiveness of Azvudine in Hospitalized Patients with COVID-19: a Retrospective Cohort Study

Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study

Adherence and Recommended Optimal Treatment to Azvudine Application for the Treatment of Outpatient COVID-19 Patients: A Real-World Retrospective Study

Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study

Oral Azvudine for Hospitalised Patients with COVID-19 and Pre-Existing Conditions: a Retrospective Cohort Study

Clinical Trials Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis

Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies

Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Early antiviral therapy of abidor combined with lopinavir/ritonavir and re combinant interferonα 2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study

Effects of Azvudine on the Low-Risk Patients Infected with COVID-19 Omicron Variants: A Retrospective Case-Control Study

Early Antiviral Treatment Contributes to Alleviate the Severity and Improve the Prognosis of Patients with Novel Coronavirus Disease (COVID-19)

Azvudine-Centered Comprehensive Therapeutic Strategy for the Treatment of COVID-19 Infection in Kidney Transplant Recipients in the Developing World: an Observational Pilot Study

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience

A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study

Effectiveness of Nirmatrelvir-Ritonavir Versus Azvudine for Adult Inpatients with Severe or Critical COVID-19

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing